Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA studyLiesbet De Bus, Mónica Crespo, Pieter Depuydt et al.|Intensive Care Medicine|2020Cited by 117
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, Antonio DiGiandomenico et al.|Critical Care|2022Cited by 93
Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID studyMassimiliano Greco, Nicolas De Schryver, Thomas De Corte et al.|Intensive Care Medicine|2022Cited by 88
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Simon Lambden et al.|The Lancet Respiratory Medicine|2023Cited by 76
Co-infection and ICU-acquired infection in COVID-19 ICU patients: a secondary analysis of the UNITE-COVID data setAndrew Conway Morris, Luis Felipe Reyes, Katharina Köhler et al.|Critical Care|2022Cited by 64